Tiplimotide
Peptideexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 1998 (NCT00001781)
Timeline
1990s
- Jan 1, 1998
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Myelin basic proteinSupplementation
MBP supplementation
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2108869 ↗
Also known as
- 83-ala-84-lys-89-leu-91-ala-mbp(83-99)
- cgp 77116
- cgp 77116
- myelin basic protein (83-99), ala(83)-lys(84)-leu(89)-ala(91)-
- myelin basic protein (83-99), alanyl(83)-lysyl(84)-leucyl(89)-alanyl(91)-
- nbi 5788
- nbi-5788
- nbi-5788
- nbi-5788
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00079495 | Phase 2 | Jul 1, 2003 | Immune Tolerance Network, Neurocrine Biosciences |
| NCT00001781 | Phase 2 | Feb 1, 1998 | National Institute of Neurological Disorders and Stroke (NINDS) |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Immune Tolerance Network | Academic/Hospital | 1 | 0 | 1 | 2003 |
| National Institute of Neurological Disorders and Stroke (NINDS) | Government | 1 | 1 | 1 | 1998 |
| Neurocrine Biosciences | For profit | 1 | 1 | 1 | 2003 |
3 organizations
Page 1 / 1